Domaine d’Intérêt Majeur (DIM)

Empowering LIfe sCiences with Innovative Technologies (ELICIT)

Call 2021

Equipment subvention

This call will be open from the **3rd of June 2021 to the 10th of September 2021**.

Exceptionally this year, Postdoc/Engineer allocation and Equipment funding will be evaluated independently, and the research project have to be link with one of these three categories:

* **Co-development of innovative technologies & methods**
* **Dissemination of Innovative Technologies for Life Sciences**
* **Prematuration project of innovative technologies for life sciences**

Applications will have to be sent to dim.elicit@pasteur.fr. We will acknowledge the receipt of all the applications within a week.

Projects will have to be written in **English.**

More details about DIM ELICIT philosophy and objectives on: <https://dim-elicit.fr/>

We are trying to provide clear information on the eligibility criteria in the call description. However, we will be happy to answer further questions and help you check the eligibility of your project prior to the submission.

For any question, please contact:

dim.elicit@pasteur.fr

or

marina.caillet@pasteur.fr

Table of content

[1. Call design : 3](#_Toc72407579)

[2. Eligibility criteria: 4](#_Toc72407580)

[3. Awards: 5](#_Toc72407581)

[4. Aims: 5](#_Toc72407582)

[5. Core technologies: 5](#_Toc72407583)

[6. End-user applications: 6](#_Toc72407584)

[7. Selection process and Evaluation criteria: 6](#_Toc72407585)

[1. Categories 7](#_Toc72407586)

[2. Thematic axis 7](#_Toc72407587)

[3. Teams 7](#_Toc72407588)

[**Team 1 (leader)** 7](#_Toc72407589)

[**Team 2** 8](#_Toc72407590)

[**Team 3.......** 8](#_Toc72407591)

[**Associated company** (if relevant) 8](#_Toc72407592)

[**Short description of the company and of its implication in the project:** 8](#_Toc72407593)

[4. History of collaboration 8](#_Toc72407594)

[5. Publications 9](#_Toc72407595)

[6. Scientific description of the project 9](#_Toc72407596)

[**Abstract** 9](#_Toc72407597)

[**Technology readiness level (mandatory for Prematuration project)** 9](#_Toc72407598)

[**Economic potential impact and strategy of Tech Transfer (mandatory for Prematuration project)** 10](#_Toc72407599)

[**Adequacy with the DIM ELICIT objectives** 10](#_Toc72407600)

[7. Resources that will be available to achieve the scientific project 10](#_Toc72407601)

[**Persons involved in the project** 10](#_Toc72407602)

[**Equipment expected to be used in the project** 10](#_Toc72407603)

[8. Additional information for salaries/fellowship 11](#_Toc72407604)

[**Host institution** 11](#_Toc72407605)

[9. Signatures 11](#_Toc72407606)

Call description – Equipment subvention

# Call design :

Depending on your project, you can apply to one of the following categories:

|  |  |
| --- | --- |
| **Categories** | **Description**  |
| **Co-development of innovative technologies and methods** | *The aim of this type of project is to set up innovative/disruptive technologies which will benefit the Life Science community.* **We will fund exclusively collaborations between:*** At least one academic research team from the Region Ile de France working on the creation & development of devices or methods, according to the 3 core technologies of the DIM (Microfluidics, Biophotonics and waves, Image analysis)

**AND*** At least one academic research team from the Region Ile de France in biology, within the 4 end-user applications of the DIM ELICIT (see section 6)

The two major partners are encouraged but not required to come from two different institutes. Additional teams can participate to the project to bring additional specific expertise without geographic limitation. Team out of the region Ile de France will not be funded. Start-ups and companies can also be associated to the project without geographic limitation.A clear statement of the **economic impact of technologies** and methods to be developed will be asked as part of the application. This aspect being an important part in the evaluation, project leaders are asked to write this part with their tech transfer department (SATT, internal departments…). Proof of concept or development of technologies/methods close to industrial applications are encouraged.  |
| **Dissemination of new technologies or methods for new applications in Life Sciences** (**non commercial methods and/or instruments)** | *The aim of this type of project is to support the establishment of competitive technology platforms and to introduce relevant prototypes in biological research environments.* **We will fund collaborations between:*** At least one academic research team from the region Ile de France working on the creation of devices or methods, according to the 3 core technologies of the DIM (Microfluidics, Biophotonics and waves, Image analysis). This team – the “Technology Team” - will set up or purchase an innovative instrument and will lead the action of dissemination;

**AND*** At least 2 additional academic research teams -“Application teams”- from the region Ile de France working on applied biology which will demonstrate the competitive advantages brought by the new technology/methods for their research. The research should fit in the scope of the 4 end-user applications of the DIM ELICIT (see section 6).

Participation of research teams belonging to different institutes are encouraged. A start-up company can be associated to the project but will not have access to fund.**We will consider projects proposing:*** The duplication in a biology environment of an existing noncommercial prototype previously developed by the Technology Team;
* The adaptation by the Technology Team of an existing prototype to fit specific applications and its implementation in the end-user environment.

The Technology Readiness Level (TRL) expected for type of project is higher than for the Co-Development project. We will not consider totally new/invalidated technologies. A preexisting publication or patent of the technology team showcasing the technology is a must. The envisioned equipment can be manufactured by a private third party under the supervision of the Technology Team.  |
| **Prematuration project of innovative technologies for life sciences** | We will fund the pre-maturation of projects aiming at the creation of technology start-ups. Higher Technology Readiness Levels can be accepted in that context compared to the Co-development and Dissemination cases mentioned above. We will accept projects up to TRL5. The project should be based on results obtained in collaborations between technology groups and application groups but does not necessarily involve an application partner at this stage. The project should highlight what key Proof-Of-Concept technical results are expected in the foreseen period, and why they will be a key step in value creation toward the incorporation of a start-up.We would typically pay for the salary of the person (post-doc, PhD…) that would become CTO or CEO of the start-up. A CV is mandatory for this type of project. We will also fund the participation of the person to the Deeptech Founders entrepreneurship training. |

To help you check whether your consortium is in the scope of this call, please note that the following **examples of consortia are NOT eligible**:

|  |  |
| --- | --- |
| **Categories** | **Non eligible cases** |
| **Co-development of innovative technologies and methods** | * Co-development with an industrial partner as one of the two major partners (Tech or Biology)
* Co-development between only several technology partners
* Co-development between only several biology/biochemistry partners
* Co-development between several members of the same lab with different expertise
 |
| **Dissemination of new technologies or methods**  | * Development of new protocols on a commercially available device, without modification of the device
 |
| **Prematuration project of innovative technologies for life sciences** | * No significant additional technology development
* Start-up already incorporated
 |

For Dissemination projects, here are some examples **regarding eligibility**

* Development by technology partner of an add-on/adaptation to a technology commercialized by a spin-off company of the lab, and dissemination in at least 2 laboratories  eligible, and highly favored if said spin-off is based in the Region Ile de France
* Development by technology partner of an add-on/adaptation to a technology commercialized by a third party, and dissemination in at least 2 biology laboratories  eligible only if the company express interest on the commercialization of the new technological developments (letter to be provided with the application)

# Eligibility criteria:

Any research team from the region Ile de France can apply with a project in line with the aims, positioning and thematic axes of the DIM. A researcher can only coordinate one project within the framework of this call but can be partner in other projects.

**A researcher that has been selected for funding in 2020 cannot apply to this call.**

The proposed project should not have been previously supported by another DIM, the SESAME program, a program from the Genopole or a collaborative project from a competitive cluster.

If you apply for equipment funding you cannot apply for postdoc/engineer allocation and vice versa.

# Awards:

In the context of this call, the DIM ELICIT will fund for each project equipment(66% max of total cost without VAT) with a maximal participation of 200k€ from DIM ELICIT

# Aims:

**The aim of this call is to promote the emergence of innovations able to address the market of instruments and technologies for Life Sciences (with potential dual applications in healthcare, agronomy or other industrial sectors), in the mid-term, in link with one of these following categories:**

|  |  |
| --- | --- |
| **Categories** | **Description**  |
| **Co-development of innovative technologies and methods** | The 2021 Co-Development Call aims at supporting interdisciplinary collaborative research projects that will combine: * First application of technologies or innovative instruments or new methods to biology, with a clear impact and transformative potential in Life Science;

**AND*** Integration in the SME and industrial value-added chain, in particular in Ile-de-France, in the area of Technologies for Life Sciences either through tech transfer or start-ups creation.
 |
| **Dissemination of new technologies or methods for new applications in Life Sciences** (**non commercial methods and/or instruments)** | The Dissemination Call 2021 aims at supporting interdisciplinary collaborative research projects that will combine: * Implementation of disruptive technologies or methods in biology, the disruptiveness criteria being assessed regarding their impact and transformative nature;

**AND** * Integration in the SME and industrial value-added chain, in particular in Ile-de-France, in the area of Technologies for Life Sciences either through tech transfer or start-ups creation.

**AND** * Integration in an open access environment for Life Sciences research teams.
 |
| **Prematuration project of innovative technologies for life sciences** | We will fund the pre-maturation of projects aiming at the creation of technology start-ups. Higher Technology Readiness Levels can be accepted in that context compared to the Co-development and Dissemination cases mentioned above. We will accept projects up to TRL5. The project should be based on results obtained in collaborations between technology groups and application groups but does not necessarily involve an application partner at this stage. The project should highlight what key Proof-Of-Concept technical results are expected in the foreseen period, and why they will be a key step in value creation toward the incorporation of a start-up.We would typically pay for the salary of the person (post-doc, PhD…) that would become CTO or CEO of the start-up. A CV is mandatory for this type of project. We will also fund the participation of the person to the Deeptech Founders entrepreneurship training.We will also fund the participation of the person to the Deeptech Founders entrepreneurship training. |

# Core technologies:

* **Microfludics**: micro droplets, lab-on-chip, organ-on-chip, 3D printing, surface patterning, low-cost technologies (paper microfluidics), submicrometric scale microfluidics, nanofluidics…
* **Biophotonic and waves**: acoustic and electromagnetic waves, super-resolution, associated sensor technologies, multiphoton microscopy, visible spectroscopy, terahertz spectroscopy, Raman, innovative probes (nanoparticles, nanosensors, ...), ontogenetic, adaptive optics, photoablation and stimulation, emission tomography positron ...
* **Image analysis:** compressive sensing, tracking, localization, digital pathology, statistical analysis, spatial analysis, harmonic analysis, optimization, automation, deep learning, cloud software deployment, augmented and immersive visualization ...

# End-user applications:

* **Single Cell, single molecule**: technology development to manipulate and to analyze single cell and single molecule in order to understand biological phenomena involved in heterogeneous populations (eg a subset of cells resistant to chemotherapy in a tumor). The ability to act / manipulate before the analytic phase is critical. Breakthrough results are expected with this type of method in immunology, developmental biology, cancer ...
* **Organs-on-chips:** In order to outperform more and more animal models, these technologies will have to fully mimic biology of tissues and organs (3D aspects, signaling, mechanobiology…). Key applications would be models to understand diseases development, toxicology assessment, drug screening…
* **Technologies for *in vivo* biology on animals models:** Animal models remain an essential and critical step to understand complex phenomena such as drug metabolism, psychiatric diseases, or tumors’ development in an organism. Thus, it is essential to rationalize the use of these models through a more and more accurate and efficient extraction of data from these experiments (ad hos microscopy devices, implanted and connected sensors…)
* **High Tech – Low Cost technologies**: Disruptive technologies to ensure affordable access to manipulation and analysis tools of biologic systems in low resources contexts like in developing countries (Low-cost “point of care” diagnosis, low-cost microscopy…)

# Selection process and Evaluation criteria:

Project selection will be organized by the [DIM ELICIT Steering Committee](https://dim-elicit.fr/dim-elicit/) and will be based on external evaluations.

Results will be announced in November 2021.

Applications will be assessed according to the following evaluation criteria:

* Innovation and originality of the proposal
* Scientific quality, implementation, timeline
* Competitive positioning
* Adequacy of resources with the proposed project
* Economic impact and tech transfer potential and perspectives

**Prematuration Projects will be given priority**

Equipment application form

**Acronym and title of the project**

1. ***Categories***

**[ ]  Co-development of innovative technologies & methods**

**[ ]  Dissemination of Innovative Technologies for Life Sciences**

**[ ]  Prematuration project of innovative technologies for life sciences**

1. ***Thematic axis***

**Core Technologies**: Tick the dominant box

|  |  |
| --- | --- |
|  | *Microfluidics* |
|  | *Biophotonics and waves* |
|  | *Image analysis*  |

**End-user applications:** Tick the dominant box

|  |  |
| --- | --- |
|  | Digital Biology: single-cell and single-molecule analysis |
|  | Organs-on-chips |
|  | Technologies for in vivo biology on animals models |
|  | High Tech at Low Cost |

# Teams

*Teams will have to work in different labs but can belong to the same research institute/structure.*

**Team 1 (leader)**

|  |  |
| --- | --- |
| Name of the PI |  |
| Email |  |
| Phone number  |  |
| Lab’s name, number and address  |  |
| COMUE’s name  |  |

Short description of the laboratory:

**(Max 10 lines)**

|  |
| --- |
|  |

**Team 2**

|  |  |
| --- | --- |
| Name of the PI |  |
| Email |  |
| Phone number  |  |
| Lab’s name, number and address  |  |
| COMUE’s name  |  |

Short description of the laboratory:

**(Max 10 lines)**

|  |
| --- |
|  |

**Team 3.......**

**Associated company** (if relevant)

|  |  |
| --- | --- |
| Person in charge  |  |
| Email |  |
| Phone Number |  |
| Company’s address |  |

**Short description of the company and of its implication in the project:**

**(Max 15 lines)**

|  |
| --- |
|  |

# History of collaboration

Have the teams already worked together?

|  |  |  |  |
| --- | --- | --- | --- |
| Yes |  | No |  |

If yes, on which occasion? **Please describe**

|  |
| --- |
|  |

# Publications

**Recent publications related to the project (max 3 per team)**

|  |
| --- |
|  |

# Scientific description of the project

**Abstract**

**(Max. 10 lines – this part is not confidential and could be published on our website if you are selected)**

|  |
| --- |
|  |

**Description of the project***:* state of the art, objectives, time table, description and figures, deliverables and project plan, innovative aspects, description of scientific projects to be conducted on the technology

For each piece of equipment requested, please specifically describe and justify it:

**(Max. 5 pages, Times 11 – confidential part)**

|  |
| --- |
|  |

**Technology readiness level (mandatory for Prematuration project)**

(Max 0,5 page, Times 11)

Please comment on the envisioned time to start-up creation/tech transfer after the completion of the project. You can use the positioning in the Technology Readiness Level scale of the European Commission.

|  |  |
| --- | --- |
| **Technology Readiness Level** | **Description** |
| TRL 1. | Basic principles observed |
| TRL 2. | Technology concept formulated |
| TRL 3. | Experimental proof of concept |
| TRL 4. | Technology validated in lab |
| TRL 5. | Technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies) |
| TRL 6. | Technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies) |
| TRL 7. | System prototype demonstration in operational environment |
| TRL 8. | System complete and qualified |
| TRL 9. | Actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space) |

|  |
| --- |
|  |

**Economic potential impact and strategy of Tech Transfer (mandatory for Prematuration project)**

(Max 0,5 page, Times 11)

Inputs of your patent office / tech transfer office are very recommended

(Prematuration projects: Min 0,5 page Max 2 pages, Times 11)

The paragraph should contain information about the intellectual property strategy, the potential market, the industrial competitors and why you could surpass them, the potential business models (what will you sell to whom and how). Figures and Graphics are welcome.

This paragraph does not need to demonstrate a ready-to-go Business Plan but must demonstrate that the team has already identified key challenges associated to the creation of the start-up. The team can openly highlight key business questions yet to be answered.

|  |
| --- |
|  |

**Adequacy with the DIM ELICIT objectives**

(Max 0,5 page, Times 11)

|  |
| --- |
|  |

# Resources that will be available to achieve the scientific project

**Persons involved in the project**

|  |  |  |
| --- | --- | --- |
| Name | Position | Percentage of implication |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**Equipment expected to be used in the project**

List the equipment the equipment that will be used in the project, except the one that will be purchased.

|  |
| --- |
|  |

# Additional information for equipment

### Total cost of the equipment

|  |  |
| --- | --- |
|  | € HT  |

### Amount of funding requested

|  |  |
| --- | --- |
|  | €  |

|  |  |
| --- | --- |
|  | % total cost |

You shall respect the maximum rate of 66% and a maximum amount of 200k€.

###

### Co-funding plan

Please indicate the amount and the percentage of implication of each co-funder.

NB: Co-funding letters signed by a qualified person will be asked to laureates before the signature of the funding agreement.

|  |
| --- |
|  |

### Host institution (Equipment)

|  |
| --- |
|  |

### Equipment localisation

|  |  |
| --- | --- |
| Laboratory : |  |
| Site : |  |

### Envisioned date of equipment purchase

|  |
| --- |
|  |

### Equipment list

Please include quotes

For internal developments assembling components into a device, no quote for small parts (< 1000 euros/piece) is required

|  |
| --- |
|  |

# Signatures

**Instead of signatures, please put all your partners in cc of your email submission.**

**Team 1 (leader)**

|  |  |
| --- | --- |
| First name, surname  |  |
| Position  |  |
| Location |  |
| Date  |  |
| Signature |   |

**Team 2**

|  |  |
| --- | --- |
| First name, surname  |  |
| Position  |  |
| Location |  |
| Date  |  |
| Signature |   |

**Team 3......**